Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics (ADMA)
NASDAQ:ADMA
ADMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.02 - $23.64
Previous CloseN/A
Volume407.39K
Average Volume (3M)2.30M
Market Cap
$3.82B
Enterprise Value$4.92B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)58.2
Beta1.29
Next Earnings
Mar 20, 2025EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding236,390,260
10 Day Avg. Volume1,884,609
30 Day Avg. Volume2,298,096
Standard Deviation0.15
R-Squared0.07
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.92
Price to Cash Flow (P/CF)38.00
P/FCF Ratio39.70
Enterprise Value/Market Cap1.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit55.30
Enterprise Value/Ebitda49.94
Forecast
1Y Price Target
$28.00Price Target Upside74.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
ADMA Biologics News
PremiumCompany Announcements
ADMA Biologics Approves 2025 Executive Compensation Package
PremiumCompany Announcements
ADMA Biologics Announces Board Resignations and Appointments
PremiumCompany Announcements
ADMA Biologics Reports Robust Q3 2024 Growth---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceADMA reported its 3Q24 financial results, delivering $119.8M in total revenue for the period, representing 12% quarter-over-quarter revenue growth, soundly beating the revenue forecast.
Revenue GuidanceADMA significantly increased revenue guidance, projecting $415M in full-year 2024 revenue and $465M in full-year 2025 revenue, which represents a sizable increase from prior revenue guidance.
Bears Say
Valuation ConcernsKey triggers behind the sell-off were a more modest than expected 2025 guide, ambiguity on bullish implications of the enhanced supply agreements, and valuation friction.
---
Ownership Overview
3.52% Insiders
20.83% Mutual Funds
12.85% Other Institutional Investors
33.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADMA FAQ
What was ADMA Biologics’s price range in the past 12 months?
ADMA Biologics lowest stock price was $5.02 and its highest was $23.64 in the past 12 months.
What is ADMA Biologics’s market cap?
ADMA Biologics’s market cap is $3.82B.
When is ADMA Biologics’s upcoming earnings report date?
ADMA Biologics’s upcoming earnings report date is Mar 20, 2025 which is in 26 days.
How were ADMA Biologics’s earnings last quarter?
ADMA Biologics released its earnings results on Nov 07, 2024. The company reported $0.163 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.033.
Is ADMA Biologics overvalued?
According to Wall Street analysts ADMA Biologics’s price is currently Undervalued.
Does ADMA Biologics pay dividends?
ADMA Biologics does not currently pay dividends.
What is ADMA Biologics’s EPS estimate?
ADMA Biologics’s EPS estimate is 0.15.
How many shares outstanding does ADMA Biologics have?
ADMA Biologics has 236,390,260 shares outstanding.
What happened to ADMA Biologics’s price movement after its last earnings report?
ADMA Biologics reported an EPS of $0.163 in its last earnings report, beating expectations of $0.13. Following the earnings report the stock price went up 14.706%.
Which hedge fund is a major shareholder of ADMA Biologics?
Currently, no hedge funds are holding shares in ADMA
---
ADMA Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.00 (74.13% Upside)
$28.00 (74.13% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
212.23%
12-Months-Change
Fundamentals
Return on Equity
35.55%
Trailing 12-Months
Asset Growth
11.93%
Trailing 12-Months
Company Description
ADMA Biologics
ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.
---
ADMA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with significant growth in revenue, EBITDA, and net income. The company revised its financial guidance upwards and highlighted strategic initiatives such as ASCENIV's production shift and ADMAlytics implementation. However, challenges persist with gross margin impacts from low-margin plasma sales, discontinuation of a product line, and supply constraints for ASCENIV.Read More>---
ADMA Stock 12 Month Forecast
Average Price Target
$28.00
▲(74.13% Upside)
Technical Analysis
Best Analysts Covering ADMA
1 Year
1 Year Success Rate
15/24 ratings generated profit
1 Year Average Return
+75.32%
reiterated a buy rating last month
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +75.32% per trade.
---